ArticleJournal of neuro-oncology2018
Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014.
Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Overall survival across registry-defined biopsy and registry-defined STR categories in glioblastoma: a population-based matched and weighted SEER study.Scientific reports · 2026Article
- Analysis of Overall Survival in High-Grade Glioma Patients Treated With Surgery and Adjuvant Therapy.Cureus · 2025Article
- Development and validation of nomogram model predicting overall survival and cancer specific survival in glioblastoma patients.Discover oncology · 2025Article
- Relative, Conditional, and Overall Survival and Causes of Death in Patients With Glioblastoma: A Retrospective Longitudinal Cohort Study.Journal of clinical medicine research · 2025Article
- Association of hospital volume with survival but not with postoperative mortality in glioblastoma patients in Belgium.Journal of neuro-oncology · 2024Article
- Do presenting symptoms predict treatment decisions and survival in glioblastoma? Real-world data from 1458 patients in the Swedish brain tumor registry.Neuro-oncology practice · 2024Article
- Patterns of care and survival in patients with multifocal glioblastoma: A Danish cohort study.Neuro-oncology practice · 2024Article
- Survival After Newly-Diagnosed High-Grade Glioma Surgery: What Can We Learn From the French National Healthcare Database?Brain tumor research and treatment · 2024Article
- Prognostic factors to predict postoperative survival in patients with recurrent glioblastoma.World neurosurgery: X · 2024Article
- Intratumoral calcification: not only a diagnostic but also a prognostic indicator in oligodendrogliomas.European radiology · 2024Article
- High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.Frontiers in oncology · 2024Review
- The benefit of complete resection of contrast enhancing tumor in glioblastoma patients: A population-based study.Neuro-oncology practice · 2023Article
- Preoperative neurocognitive function as an independent survival prognostic marker in primary glioblastoma.Neuro-oncology practice · 2023Article
- Glioblastoma management in a lower middle-income country: Nationwide study of compliance with standard care protocols and survival outcomes in Ukraine.Neuro-oncology practice · 2023Article
- Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period.Neuro-oncology practice · 2023Article
- What predicts survival in glioblastoma? A population-based study of changes in clinical management and outcome.Frontiers in surgery · 2023Article
- Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.OncoTargets and therapy · 2023Review
- Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations.Cancer biology & medicine · 2022Review
- Review
- Prediagnosis epilepsy and survival in patients with glioma: a nationwide population-based cohort study from 2009 to 2018.Journal of neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAs many glioblastoma patients are in a poor condition they are unable to undergo the full treatment documented in clinical trials. We aimed to examine the survival and its relationship to clinical characteristics and treatment in a nationwide population of glioblastoma patients in Denmark.
methodsWe included prospectively recorded clinical data from 1364 adult patients with histologically verified glioblastoma from the Danish Neuro-Oncology Registry, 2009-2014.
resultsThe age standardized incidence rate was 6.3/100,000 person-years for males and 3.9 for females and the median age was 66 years. The median overall survival was 11.2 months. There was an independently significant prognostic effect of age, performance status, cognitive symptoms, tumor diameter, multifocality, crossing midline, and contrast enhancement. For partial and total resection compared to biopsy only, the adjusted risk of dying was reduced by 43% (HR [CI] 0.57 [0.48-0.68]) and 51% (0.49 [0.40-0.60]), respectively. For patients receiving a partial and full radiochemotherapy regimen compared to no postsurgical treatment, the risk reduction was 56% (HR [CI] 0.44 [0.37-0.53]) and 70% (0.30 [0.25-0.35]), respectively. The full radiochemotherapy regimen was only allocated to 50% of the patients, 29% among the oldest (70+ years) and 60% among the younger (18-69 years).
conclusionsGlioblastoma patients had a poor overall survival but with several specific independent prognostic factors. Extensive cancer treatment was associated with an increasing survival in all age groups, but only half of the patients were sufficiently fit for a full regimen of postoperative combined radiochemotherapy.
Indexed as
Identifiers
29754199What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.